Patients with MSI-H tumours, i.e., MMR-deficient, have better survival when compared to those with MSS tumours, i.e., MMR-proficient. We did not find a significant difference between MSI-H tumours and MSS tumours (p = 0.432) most likely due to the small number of data points. Interestingly, MMR status has been shown to predict responsiveness to adjuvant treatments. The gene discussed is MRC1; the disease is neoplasm.